Genkyotex annonce l'approbation du regroupement d'actions par ses actionnaires et fait le point sur son activité

information fournie par Boursorama •25/01/2019 à 07:00

o All patients in the phase 2 trial with GKT831 in PBC have completed a 12-week treatment and approximately 75% have completed the full 24-week treatment period
o No dropouts or treatment interruptions due to pruritus have been reported to date

"I would like to thank our shareholders who have shown once again their support for Genkyotex with the approval of this reverse stock split," said Elias Papatheodorou, Chief Executive Officer of Genkyotex. "We believe that the reverse stock split is a critical step in our larger strategic initiative to increase global visibility for Genkyotex. We continue to be involved in a number of activities to increase the exposure of Genkyotex to the international markets."

Pour recevoir toute l'information financière de Genkyotex en temps réel, faites-en la demande par mail à genkyotex@newcap.eu. Votre inscription sera immédiate.